Feb 2025 | Issue:02

Veeda™ Lifesciences

THE VEEDA NEWSLETTER

Excited to Be Part of DCAT Week 2025

Bringing scientific rigor & robust in-house infrastructure to support even the most complex generics studies, ensuring market exclusivity with minimal delays. Connect and collaborate!

Book a Meeting Now

Inside Veeda Group: February 2025

info@veedalifesciences.com
www.veedalifesciences.com

Excellence In Everything

From the CEO's DESK

Veeda™ Lifesciences

I believe we are at a defining moment for the pharma industry one where technology, data, and strategic vision will separate leaders from followers.

From Volume to Value – Prioritizing high-impact, differentiated innovation
AI & Digital Transformation – Reshaping R&D, manufacturing, and patient engagement.
Strategic Leadership – Driving progress through bold, data-driven decisions.
AI is no longer just an enabler—it's a catalyst for change. From optimizing clinical development and patient recruitment to strengthening real-world evidence and bioanalytical solutions, the industry is at an inflection point. Generative AI presents an opportunity to enhance efficiency, scalability, and decision-making across the pharma value chain.

At Veeda Lifesciences, we recognize this shift and are focused on embedding AI and advanced analytics into our operations—unlocking new efficiencies and accelerating breakthroughs in clinical research. The industry is moving fast, and the winners will be those who lead with conviction, agility, and a relentless focus on impact.

Best Regards,
Dr. Mahesh Bhalgat
Group CEO & MD, Veeda Lifesciences

info@veedalifesciences.com
www.veedalifesciences.com

Veeda Voice



Biologics Workshop 2025 in Goa sparks insightful discussions

A milestone moment at Biologics Workshop 2025 in Goa! We unveiled our renewed brand identity, reinforcing our mission to drive innovation in biotherapeutics..

Dr. Kiran Marthak shares insights at Atal Incubation Centre CCMB

Veeda Lifesciences actively engages with startups! Dr. Kiran Marthak shared expertise on early-stage clinical trials at AIC-CCMB's workshop on regulatory compliance for novel healthcare solutions.



Podcast Spotlight on Bioanalysis for USFDA Compliance

Veeda Lifesciences pioneers advanced bioanalytical methods, ensuring precise Ferric Carboxymaltose measurement with SEC-LC-ICP-MS and ICP-OES, setting new benchmarks in bioequivalence studies.

Dr. Mahesh Bhalgat visits Clinical & Bioanalytical Facility (Vedant)

A dynamic interaction at Vedant Facility! Dr. Mahesh Bhalgat shared his expertise on overcoming challenges, adopting new methodologies, and driving innovation in bioanalytical sciences.

Industry INSIDER

Veeda™ Lifesciences

Sensorion receives DMC recommendation to continue the Audiogene phase 1/2 trial of SENS-501

Sensorion, a clinical-stage biotech company, announced that the Data Monitoring Committee (DMC) has recommended continuing the Phase 1/2 Audiogene trial of SENS-501, its gene therapy aimed at treating congenital deafness caused by OTOF gene mutations.

Read More



New study shows significant improved clinical accuracy with Nevisense for both US & German dermatologists

SciBase Holding AB (SciBase), a leading developer of augmented intelligence-based solutions for skin disorders, announced that an article comparing US and German dermatologists improved biopsy decisions following the addition of Nevisense (EIS) as a decision support tool was recently published in SKIN, the Journal of Cutaneous Medicine.

Read More

Senores Pharma acquires ANDA for roflumilast 250 mcg and 500 mcg tablets from Breckenridge Pharma

Senores Pharmaceuticals through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPL) has signed an agreement to acquire the US FDA approved Abbreviated New Drug Application (ANDA) for 'Roflumilast' 250 mcg and 500 mcg tablets from Breckenridge Pharmaceutical.

Read More

Zydus receives US FDA final approval for generic Duexis tablets, 800 mg/26.6 mg

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food & Drug Administration (FDA) to manufacture ibuprofen & famotidine tablets, 800 mg/26.6 mg. (USRLD: Duexis tablets, 800 mg/26.6 mg).

Read More

Granules India enters peptide segment and CDMO business by acquiring Senn Chemicals AG

Granules India, a generic drugmaker, is foraying into the peptide segment and contract development and manufacturing organisation (CDMO) business with acquisition of Swiss firm Senn Chemicals AG. Senn develops & manufactures, peptides and peptides based applications for its global customers, providing contract research, development, and manufacturing services.

Read More

J&J reports positive Phase 3 ASTRO study results on Tremfya SC for moderate to severe ulcerative colitis.

Johnson & Johnson (J&J) announced data from the phase 3 ASTRO study of Tremfya (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ulcerative colitis (UC) at the 20th Congress of the European Crohn's and Colitis Organization (ECCO).

Read More

Industry INSIDER

Veeda™ Lifesciences

Sandoz launches biosimilar Pyzchiva in US, offering new treatment for around 12 million patients

Sandoz, the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva (ustekinumab-ttwe) in the US. From February 24, the medicine is commercially available to patients across the US.

Read More

Amgen opens new technology and innovation site in Hyderabad, to invest $200 million through 2025

Amgen has opened the Amgen India new technology and innovation site in Hyderabad. The company plans to invest $200 million through 2025, with additional sustained investments planned over the coming years.

Read More

China NMPA accepts NDA and grants priority review designation to Innovent's ipilimumab injection.

Innovent Biologics announces that China's NMPA has accepted the NDA for ipilimumab injection (anti-CTLA-4) and granted Priority Review for its combination with sintilimab as a neoadjuvant treatment for resectable MSI-H/dMMR colon cancer.

Read More

GSK completes acquisition of Boston-based, clinical-stage biopharma company, IDRx, Inc.

GSK plc announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of gastrointestinal stromal tumours (GIST).

Read More

Exporters seek urgent policy intervention as currency depreciation hits exports to Africa

Africa's pharmaceutical industry is facing a severe crisis as the depreciation of local currencies, coupled with geopolitical tensions continues to disrupt trade. Indian pharma exporters have raised alarm over the drastic decline in pharmaceutical exports, which have plummeted by up to 50% in some regions.

Read More



Indian healthcare sees need to strengthen AI education as technology bolsters remote patient access

The Indian healthcare industry is now increasingly seeing the need to strengthen education in artificial intelligence (AI) as technology adoptions boost remote patient access. Hari Subramaniam, founder & CEO, Lifesigns noted that AI is an inevitable force reshaping healthcare worldwide.

Read More

Employee SPOTLIGHT

Veeda™ Lifesciences

Celebrating Tradition & Togetherness of Vasilopita at Veeda's Europe Office

Our Athens team welcomed 2025 with the Greek tradition of cutting the Vasilopita, joined by COO James Brook. This heartfelt celebration symbolized unity, good fortune, & a prosperous year ahead!

Read More!



Dr. Sanjib Banerjee COO (Biopharma Services), on BioTheraputics Development

Watch our COO(Biopharma Services) as he shares how Veeda Lifesciences accelerates biotherapeutics development with expertise and innovation.

Watch Now!

#UnitedByUnique in the Fight Against Cancer

Cancer impacts each life differently, but we stand together. On World Cancer Day, we raise awareness, advocate for better care, and bridge the gap between therapies and patient needs.

Learn More!

info@veedalifesciences.com

www.veedalifesciences.com

Contact Us

Global Offices

- India
- Greece
- Italy
- Ireland



info@veedalifesciences.com

www.veedalifesciences.com

Excellence In Everything